Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer.
By A. Partridge, Philip S. Wang, E. Winer, J. Avorn. Journal of Clinical Oncology, 2003
681 citations recorded by the source corpus.
Subfields: Family Practice, Genetics, Pharmacology
View Paper: https://www.semanticscholar.org/paper/af630e0616f3495f05c0035812bac5db97e70ae5
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- S. Greenfield
- E. Stovall
- M. Kwan
- M. Hewitt
Citations in the corpus
- From cancer patient to cancer survivor : lost in transition (2006, background): “…is based on recent comprehensive reviews relating to breast cancer treatment and late effects (Burstein and Winer, 2000; Shapiro and Recht, 2001; Partridge et al., 2001, 2003; Emens and Davidson, 2003; Hurria and Hudis, 2003; Kattlove and Winn, 2003; Harris et al., 2004; Mrozek and Shapiro,…”
- Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer (2010, background): “Several other investigators have reported rates of nonadherence to HT ranging from 30 to 50% [5, 7, 10, 32, 33].”
- Adherence to Adjuvant Hormonal Therapy among Breast Cancer Survivors in Clinical Practice: A Systematic Review (2012, neutral): “Similarly, mean or median MPR ranged from 58 to 93 % [9, 10, 23, 47], measured at various time intervals.”